BioCentury
ARTICLE | Financial News

Dermatology play Revance sets IPO range

January 28, 2014 12:51 AM UTC

Revance Therapeutics Inc. (Newark, Calif.) amended its IPO on NASDAQ and now plans to sell 5 million shares at $14-$16. At the $15 midpoint, the company would raise $75 million and be valued at $253.2...